New Indian Health Magazine Features EECP® Therapy In Its Cover Story 

Vasomedical Applauds the International EECP® Therapist Association Call for International EECP® Therapy Week in Recognition of American Heart Month

Chapter Dedicated to EECP® Therapy in New Textbook on Coronary Artery Disease

Vasomedical Recorded Record Net Income of $2.47 Million for the Second Quarter of Fiscal 2012

More >>

January 12, 2012

Vasomedical and EECP® Therapy Presented at the OneMedForum2012 in San Francisco

CEO Dr. Jun Ma also provided a unique perspective as an invited panelist on the China Forum

WESTBURY, NY (January 12, 2012) – Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, announced today that Dr. Jun Ma, President and CEO of Vasomedical delivered a presentation about the company and its core technology, EECP® therapy, at the OneMedForumSF 2012 currently being held in San Francisco, CA this week.

The OneMedForum is an annual emerging company finance conference that brings together the world’s most promising emerging companies, investors and strategic partners in the healthcare arena.  Companies presenting at the Forum encompass the spectrum of healthcare innovators that include Cardiology, Dermatology, Oncology, Genetics, Orthopedics and others who offer new approaches to products and services for improving the healthcare system. OneMedForum is one of the largest gatherings for healthcare financiers to meet with the most promising medical devices, biothechnology, specialty pharma and health information growth companies.

Dr. Jun Ma also participated as an invited guest panelist in the China Forum segment of the program discussing doing business in China.  The China Forum gives leading Chinese and US entrepreneurs, executives and investors the opportunity to discuss the growing opportunity in the rapidly expanding Chinese healthcare sector.  Having been involved in many China-related business transactions including mergers and acquisitions, joint venture and contract manufacturing in various industry and, particularly, the acquisition by Vasomedical of two medical device companies in China this past year, Dr. Ma’s experience provided a unique insight into the implementation of growth strategies which enabled Vasomedical to not only improve its product margin but also capitalize on opportunities in this lucrative market. Dr. Ma and the panel addressed such topics as:

1. Entering China – how does a healthcare or life science company intelligently enter this market?
2. Structuring Partnerships – finding the right partner and options for structuring deals in China.
3. Intellectual Property – how China’s effort to foster its creative sector has impacted IP rights.
4. The Power of Brands – how Chinese desire for western branded products creates opportunities.

“While most people think that doing business in China is simply a way to lower production costs,” stated Dr. Ma, “Vasomedical has seized the opportunity to acquire companies, whose expansion in the vastly growing Chinese and global healthcare market creates future marketing and sales opportunities for Vasomedical products.”  Dr. Ma said that “in order for companies to grow successfully and add shareholder value in today’s economic environment, they must constantly be looking for new products and new markets.”

For further information on EECP® therapy or other Vasomedical products visit the Vasomedical web sites at: www.eecp.com or www.vasomedical.com.

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.